Thomas L. Pulliam

Statistics

Publications

Citations

215

H-Index

Active since

2018

Affiliations

The University of Texas Health Science Center at Houston(Current)

University of Houston

The University of Texas MD Anderson Cancer Center

Baylor College of Medicine

Michael E. DeBakey VA Medical Center

Thomas L. Pulliam is an author at The University of Texas Health Science Center at Houston specializing in oncology, cancer cell signaling, and molecular oncology.

ORCID

Publications per year

2018–2023

Publications

GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling

Mark A. White, Efrosini Tsouko, Chenchu Lin et al. · Endocrine Related Cancer · 2018 · 75 citations · Full text

Life Sciences, Endocrinology, Oncology +17

Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling

Chenchu Lin, Alicia M. Blessing, Thomas L. Pulliam et al. · Oncogene · 2021 · 68 citations · Full text

Life Sciences, Molecular Biology, Oncology +14

Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes

Benjamin J. Eduful, Sean O’Byrne, Louisa Temme et al. · Journal of Medicinal Chemistry · 2021 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity

Dominik Awad, Pham Hong Anh Cao, Thomas L. Pulliam et al. · Cancer Research · 2023 · 28 citations · Full text

Life Sciences, Biochemistry, Oncology +17

Systemic Ablation of Camkk2 Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer

Thomas L. Pulliam, Dominik Awad, Jenny Han et al. · Cells · 2022 · 11 citations · Full text

Medicine, Molecular Biology, Oncology +17

1–5 of 5